ESC-HFA 2024: Late-Breaking Science Video Collection
Published: 14 May 2024
-
Views:
1067
-
Likes:
7
-
Views:
1067
-
Likes:
7
-
Up Next -
4m 46s -
4m 40sPart 2 | Session 7 FINE-HEART: Design & Baseline Characteristics -
11m 58sPart 2 | Session 8 HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
-
15m 26sPart 1 | Session 1 HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Harriette Van Spall, Mark Petrie
-
10m 15sPart 1 | Session 2 Late-Breaker Discussion: The TITRATE-HF Study Harriette Van Spall, Jasper J Brugts
-
12m 4sPart 1 | Session 3 Late-Breaker Discussion: Insights from the STEP-HFpEF Harriette Van Spall, Mikhail Kosiborod
-
8m 37sPart 1 | Session 4 Late-Breaker Discussion: Findings from PACT-HF Harriette Van Spall, Tauben Averbuch
-
2m 45sPart 2 | Session 1 Remote Patient Monitoring for Patients With Heart Failure: TELESAT Nicolas Girerd
-
5m 3sPart 2 | Session 2 Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF Michael Kiernan
-
7m 19sPart 2 | Session 3 Aspirin Avoidance after Implantation of a Fully Magnetically Levitated LVAD: ARIES HM3 Finn Gustafsson
-
5m 24sPart 2 | Session 4 Timing of Cardio-Kidney Protection with SGLT2i Muthiah Vaduganathan
Overview
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024.
Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests.
For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).
MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of ejection fraction. Patients were randomly assigned (1:1) to haemodynamic monitoring (CardioMEMS-HF system, Abbott Laboratories) or standard care. Findings presented at Heart Failure 2023 showed PA-guided therapy in addition to SoC with contemporary GDMT resulted in a significant improvement in quality of life and substantial reduction in total HFHs.
This analysis investigated all clinically relevant endpoints in patients with chronic heart failure in predefined subgroups of age, gender, ejection fraction, etiology, atrial fibrillation, diabetes and ICD therapy. There were also exploratory subgroups for obesity, renal function and NTproBNP levels. The patient's quality of life, heart failure hospitalisations and mortality were assessed as endpoints. Findings showed an overall consistent treatment effect of PA-guided therapy in patients with chronic heart failure across all predefined and exploratory subgroups.
Interview Questions:
- What is the importance of this subgroup analysis?
- Could you remind us of what we already know from MONITOR-HF?
- What was the study design and patient population of this predefined subgroup analysis?
- What were the key findings?
- What do these findings add to the data we already know from MONITOR-HF?
- What are the next steps?
Recorded on-site at HFA 2024, Lisbon.
Support: This is an independent interview conducted by Radcliffe Cardiology.
Editor: Jordan Rance
Video Specialist: Tom Green, Oliver Miles
Interviewer: Jonathan McKenna
Faculty Biographies
Jasper J Brugts
Heart Failure Cardiologist
Dr Jasper J Brugts is a Heart Failure Cardiologist at Erasmus University Medical Centre, Rotterdam, NL.
He is also a clinical epidemiologist and clinical trialist.
Comments